{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:30:46Z","timestamp":1772782246782,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.yebeh.2016.06.041","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T16:00:17Z","timestamp":1469462417000},"page":"132-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Efficacy and tolerability of perampanel in ten patients with Lafora disease"],"prefix":"10.1016","volume":"62","author":[{"given":"Danielle","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.06.041_bb0005","first-page":"256","article-title":"Progressive myoclonus epilepsy of Lafora","author":"Serratosa","year":"2012"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jmg.40.9.671","article-title":"Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22","volume":"40","author":"Chan","year":"2003","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ebcr.2013.07.003","article-title":"Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)","volume":"1","author":"Schorlemmer","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","article-title":"Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel","volume":"2","author":"Dirani","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0035","first-page":"361","article-title":"The unified myoclonus rating scale","volume":"89","author":"Frucht","year":"2002","journal-title":"Adv Neurol"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/humu.9376","article-title":"Lafora progressive myoclonus epilepsy mutation database-EPM2A and NHLRC1 (EMP2B) genes","volume":"26","author":"Ianzano","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1528-1167.2006.00479.x","article-title":"Clinical and genetic findings in 26 Italian patients with Lafora disease","volume":"47","author":"Franceschetti","year":"2006","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2016.06.041_bb0050","first-page":"168","article-title":"The portal for rare diseases and orphan drugs","volume":"4","author":"Singh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0055","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy. A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0887-8994(00)00276-9","article-title":"Lafora's disease: towards a clinical, pathologic, and molecular synthesis","volume":"25","author":"Minassian","year":"2001","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-7-7","article-title":"Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease","volume":"7","author":"Ortolano","year":"2014","journal-title":"Mol Brain"},{"key":"10.1016\/j.yebeh.2016.06.041_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2016.03.008","article-title":"Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease","author":"Mu\u00f1oz-Ballester","year":"2016","journal-title":"Acta Biochim Biophys Acad Sci Hung"},{"issue":"7","key":"10.1016\/j.yebeh.2016.06.041_bb0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016302268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016302268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:06:56Z","timestamp":1718712416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016302268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":17,"alternative-id":["S1525505016302268"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.06.041","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of perampanel in ten patients with Lafora disease","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}